-
-
-
-
-
-
-
Pre-Open Stock Movers 05/22: (XSPA) (TTOO) (OSUR) Higher; (GERN) (CFRX) (ICPT) Lower (more...)
-
-
-
-
-
-
-
Dynavax Provides U.S. Regulatory Update on HEPLISAV-B(TM) Following FDA Advisory Committee Meeting
-
-
-
-
-
-
-
Pre-Open Movers 04/03: (NVCR) (STDY) (APOP) Higher; (UTHR) (ACOR) (ACN) Lower (more...)
-
-
-
-
-
-
-
Dynavax Announces FDA Acceptance for Review of Its Complete Response to November 2016 CRL and PDUFA Action Date for HEPLISAV-B(TM)
-
-
-
-
-
-
-
Dynavax (DVAX) Receives Request for More Info from U.S. FDA Over HEPLISAV-B BLA
-
-
-
-
-
-
-
Dynavax Presents New Efficacy Data on Hepatitis B Vaccine, HEPLISAV-B(TM), in Adults With Type 2 Diabetes at ADA Scientific Sessions
-
-
-
-
-
-
-
Dynavax Presents Pivotal Phase 3 Data Showing HEPLISAV-B(TM) Provides Significantly Higher Protection Against Hepatitis B Than Engerix-B(R)
-
12,349 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All